Medicxi unveils €500m fund for asset-centric biotechs

Core Insights - Medicxi has launched a €500m ($580m) fund named Medicxi V to support innovative biotech companies, highlighting concerns about the European commercial landscape compared to the US [1][5] Fund Details - The new fund will focus on asset-centric investments, supporting drug hunters and entrepreneurs in creating biotechnology companies, and will also consider existing companies with strong asset value [2][4] - This is Medicxi's sixth fund, bringing the total raised to over €2bn, with a history of backing companies that have achieved successful exits [3][4] Investment Strategy - Historically, Medicxi has allocated approximately 75% of its capital to European assets and 25% to US assets, with the current fund expected to allocate 20-30% to US-derived assets [4] - The firm emphasizes its unique connections to leading global pharmaceutical companies and a strong team of drug hunters and clinicians as key factors in its success [4] Market Context - The announcement of the fund comes at a time when the European investment scene is cooling, despite an overall increase in biotech venture funding in the second half of 2025 [5]